Vaxil Bio Ltd.
Vaxil Bio Ltd.
Your view on VXL.V
Overview
What the company does, where it operates, and who runs it.
About Vaxil Bio Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gadi Levin CPA,
- Headquarters
- 3400 One First Canadian Place, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gadi Levin CPA,
- Headquarters
- 3400 One First Canadian Place, Toronto, ON, CA
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma.
It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine.
The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice.
The company was founded in 2006 and is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vaxil Bio Ltd., and the rating behind it. VXL.V last traded at C$0.15, 1.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vaxil Bio Ltd.. Starting points for Vaxil Bio Ltd.: P/E 1.5, EPS C$0.10, beta -1.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vaxil Bio Ltd.. Vaxil Bio Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vaxil Bio Ltd.. Trailing twelve-month EPS for Vaxil Bio Ltd. stands at C$0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vaxil Bio Ltd.. Vaxil Bio Ltd. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vaxil Bio Ltd. valued side by side against its closest peers. Vaxil Bio Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vaxil Bio Ltd., and how their positions are changing. At a C$410,937 market value, institutional positions materially move Vaxil Bio Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vaxil Bio Ltd. executives and directors. Shares of Vaxil Bio Ltd. have traded between C$0.01 and C$0.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vaxil Bio Ltd.. Vaxil Bio Ltd. is a C$410,937 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vaxil Bio Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vaxil Bio Ltd.. Coverage tracks Vaxil Bio Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.